品系技术类型
研究领域
返回上一页
C57BL/6JGpt-H11em1Cin(K18-hACE2)/Gpt
H11-K18-hACE2|Strain
NO.T037657
Knockin(KI)
登录认证后查看价格,点我登录
我的购物车 ({{cartSize}})
C57BL/6JGpt-H11em1Cin(K18-hACE2)/Gpt
H11-K18-hACE2|Strain
NO.T037657
Knockin(KI)
我的购物车 ({{cartSize}})
C57BL/6JGpt-H11em1Cin(K18-hACE2)/Gpt
H11-K18-hACE2|Strain
NO.T037657
Knockin(KI)
- 性别： --
- 周龄： --
- 基因型： --
- 选择数量：
- --
¥--
我的购物车 ({{cartSize}})
C57BL/6JGpt-H11em1Cin(K18-hACE2)/Gpt
H11-K18-hACE2|Strain
NO.T037657
Knockin(KI)
性 别
周 龄
基因型
*以发货时库存基因型为准
小鼠分类
- 选择数量：
-
¥--
小计: ¥{{good.oprice}}原价: ¥{{good.price}}{{good.discount}} 折
小计: ¥{{good.price}}
加入购物车
加入购物车
我的购物车 ({{cartSize}})
- 基本信息
- 基因官方名：ACE2,H11
- 基因全名：angiotensin I converting enzyme 2
- 基因别名：ACEH,hACE2
- NCBI：59272
- 染色体：Chr 11
- 销售状态：IF(正常销售)
- 保存方式： 活体,冷冻
- 品系背景：[N000013] C57BL/6JGpt
- 微生物等级： SPF级
- 品系策略： 登录后查看品系策略，点我登录
- 品系策略： T037657.H11-K18-hACE2 strain info.pdf T037657.H11-K18-hACE2 品系资料.pdf T037657.H11-K18-hACE2 Strategy.pdf
- 研究领域：人源化模型,基因人源化模型
- 领域描述：1.SARS-CoV-2的机制研究;2.SARS-CoV-2的疫苗或者抑制剂药效及安全性评价;3.自身免疫病研究;4.新冠疾病相关。
- 发表文献：
Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2 https://doi.org/10.1016/j.antiviral.2023.105541 Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice https://doi.org/10.1016/j.virs.2022.05.006 SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration https://doi.org/10.1038/s41392-021-00719-9 Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics https://doi.org/10.1038/s41467-021-25153-x Sequential infection with H1N1 and SARS-CoV-2 aggravated COVID-19 pathogenesis in a mammalian model, and co-vaccination as an effective method of prevention of COVID-19 and influenza https://doi.org/10.1038/s41392-021-00618-z Coinfection with influenza A virus enhances SARS-CoV-2 infectivity https://doi.org/10.1038/s41422-021-00473-1 SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19 https://doi.org/10.1186/s13045-020-00954-7 A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core http://doi.org/10.1016/j.ebiom.2022.104297 In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2 https://doi.org/10.1016/j.antiviral.2022.105450 NSUN2-mediated M(5)c methylation of IRF3 mRNA negatively regulates type I interferon responses during various viral infections https://doi.org/10.1080/22221751.2023.2178238 Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2 https://doi.org/10.1073/pnas.2202820120 Inhalation delivery of dexamethasone with iSEND nanoparticles attenuates the COVID-19 cytokine storm in mice and nonhuman primates https://doi.org/10.1126/sciadv.adg3277 Soluble CD4 effectively prevents excessive TLR activation of resident macrophages in the onset of sepsis https://doi.org/10.1038/s41392-023-01438-z Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge https://doi.org/10.1038/s41392-023-01615-0 A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir https://doi.org/10.1038/s41392-023-01587-1 Independent Protection and Influence of the Spike-Specific Antibody Response of SARS-CoV-2 Nucleocapsid Protein (N) in Whole-Virion Vaccines https://doi.org/10.3390/vaccines11111681 Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir https://doi.org/10.1038/s41467-023-42102-y Intranasal mask for protecting the respiratory tract against viral aerosols https://doi.org/10.1038/s41467-023-44134-w Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants https://doi.org/10.1128/jvi.01279-23 Preclinical evaluation of the SARS-CoV-2 M(pro) inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir https://doi.org/10.1038/s41564-024-01618-9 An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza https://doi.org/10.1038/s41541-024-00857-5 An optimized high-throughput SARS-CoV-2 dual reporter trans-complementation system for antiviral screening in vitro and in vivo https://doi.org/10.1016/j.virs.2024.03.009 Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice https://doi.org/10.1186/s13046-024-03011-0 Helminth alleviates COVID-19-related cytokine storm in an IL-9-dependent way https://doi.org/10.1128/mbio.00905-24. The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development https://doi.org/10.1080/22221751.2024.2353302 Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1 https://doi.org/10.1016/j.celrep.2024.114338 A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug https://doi.org/10.1038/s41419-024-06802-7 Sanhan Huashi Formula and Its Bioactive Compounds Exert Antiviral and Anti-Inflammatory Effects on COVID-19 https://doi.org/10.1016/j.eng.2024.07.007 Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2 https://doi.org/10.3389/fimmu.2024.1416375 A decavalent composite mRNA vaccine against both influenza and COVID-19 https://doi.org/10.1128/mbio.00668-24
*使用本品系发表的文献需注明：H11-K18-hACE2 mice（Strain NO.T037657）were purchased from GemPharmatech (Nanjing, China).
